Cellnovo, Home Diagnostics Inc form strategic alliance
LONDON Cellnovo, a London-based medical device company, and Home Diagnostics, a leader in diabetes products, on Thursday announced a strategic alliance that involves integrating technologies and developing distribution opportunities for Cellnovo’s insulin-patch pumps.
The partnership allows both companies to accelerate their growth and has the potential to transform the pump industry, the companies stated in a joint press release. The first phase of the agreement calls for the inclusion of Home Diagnostics TRUE blood glucose technology in the Cellnovo wireless mobile handset. The companies will also begin exploring ways to leverage Home Diagnostics’ distribution network to expand Cellnovo’s presence in the United States and other countries.
“We are extremely excited about our partnership with Home Diagnostics,” said Bill McKeon, Cellnovo CEO. “On a technical level, it will provide our customers with the most advanced blood-glucose monitoring technology available today within our mobile handset. From a business perspective, it provides an extensive distribution network that includes 45,000 points of distribution, leading insurance companies and major product order suppliers.”
The Home Diagnostics blood glucose unit will operate as a built-in meter within the Cellnovo handset, enabling patients to monitor their blood sugar using touchscreen controls and TRUEresult and TRUEtest Test Strips. Like all information in the handset, the glucose readings will be automatically stored and sent wirelessly to physicians, clinicians and family members.
“Our agreement with Cellnovo allows us to leverage the emerging opportunities in the insulin pump market through the most innovative pump system in the industry,” said Joseph Capper, HDI president. “We look forward to helping Cellnovo bring the convenience, ease-of-use and wireless capabilities of their visionary product to diabetes patients throughout the U.S. and beyond.”
The Cellnovo pump, which is available in three models, is a small patch pump that features a wireless, touchscreen operation. With the integration of the Home Diagnostics blood glucose meter, patients can monitor their glucose levels using the same handset that records their insulin use, daily meals and activity levels, making diabetes management easier and more accurate.
“The combination of Home Diagnostics’ leadership technology and its significant distribution channels positions us to not only drive new advancements in health care, but to also bring greater freedom and convenience to diabetes patients worldwide,” McKeon said.
McNeil Consumer Healthcare temporarily suspends operations in Pa. facility
FORT WASHINGTON, Pa. In a statement released Tuesday, McNeil Consumer Healthcare stated: “The quality issues that [the Food and Drug Administration] has observed, many of which we had recently identified in our own quality reviews and communicated to the FDA, are unacceptable to us, and not indicative of how McNeil Consumer Healthcare intends to operate.”
McNeil Consumer Healthcare last week voluntarily recalled all lots that have not yet expired of certain over-the-counter children’s and infants’ liquid products in consultation with the Food and Drug Administration. The agency suggested that McNeil’s Fort Washington, Pa. plant may not be compliant with Good Manufacturing Practices.
“Some of the products included in the recall may contain a higher concentration of active ingredient than is specified; others may contain inactive ingredients that may not meet internal testing requirements; and others may contain tiny particles,” the FDA stated on its Web site.
Both the FDA and McNeil suggested the risk for adverse events associated with the recalled products was relatively low.
Following the recall, McNeil has temporarily suspended production at its Fort Washington production facility. “We will not restart operations until we have taken the necessary corrective actions and can assure the quality of products made there,” McNeil stated. “We will continue to work in close consultation with the FDA to take corrective action and ensure that our quality operations meet the high standards that consumers expect from us.”
Bayer Diabetes Care, Nick Jonas encourage consumers to ‘Give Back’
TARRYTOWN, N.Y. Bayer Diabetes Care on Tuesday announced its sponsorship of the contest “Give Back. Simply Win.” — a program that’s expected to shine a spotlight on people with diabetes who are making a difference in their local communities.
Three grand prize winners will meet singer Nick Jonas and Bayer will donate $5,000 to three not-for-profit charitable causes, one selected by each winner.
Bayer’s “Give Back. Simply Win.” contest was designed to reward people with diabetes for their charitable efforts. It is open to people with diabetes in three age categories: 6 to 12, 13 to 17 and 18-plus years.
Entries will be accepted through Aug. 5.
Nick Jonas, now 17, was diagnosed with Type 1 diabetes when he was 13. Since he publicly announced his diagnosis, he has become widely recognized not only for his musical talents, but also for his efforts to inspire people with diabetes and give back to fans that inspire him.
“One of the things we’ve been so impressed with is how much people with diabetes are doing for their communities,” Jonas said. “Bayer and I hope that through this contest we can call attention to them and thank people with diabetes who support and inspire others, whether it be through volunteering or fundraising.”